The phase I/II trial studies the side effects and best dose of panitumumab-IRDye800 in diagnosing participants with malignant glioma who undergo surgery. Panitumumab-IRDye800 can attach to tumor cells and make them more visible using a special camera during surgery, which may help surgeons better distinguish tumor cells from normal brain tissue and identify small tumors that cannot be seen using current imaging methods.
1 Primary · 3 Secondary · Reporting Duration: 1 year
11 Total Participants · 3 Treatment Groups
Primary Treatment: Cohort 2 -100mg panitumumab-IRDye800 · No Placebo Group · Phase 1 & 2
Age 18+ · All Participants · 3 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: